Multidrug resistance: A clinical approach

Current Opinion in HIV and AIDS

Volumn 4, Issue 6, 2009, Pages 499-506

  Yazdanpanah, Yazdan ^a  

^a CENTRE HOSPITALIER DE TOURCOING   (France)

Author keywords

HIV; Multidrug resistant virus; Treatment experienced patients

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; FOSCARNET; INTEGRASE INHIBITOR; LOPINAVIR; MARAVIROC; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE; TIPRANAVIR; ZIDOVUDINE;

CLINICAL RESEARCH; CLINICAL TRIAL; DRUG BINDING; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIVER TOXICITY; MEDICAL DECISION MAKING; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 70350557638     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328331c478     Document Type: Review

References (41)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 3 November 2008. pp. 1-139. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
2. Schöller M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir boosted with ritonavir in healthy subjects [abstract 583]. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, CO.
3. Leith J, Walmsley S, Katlama C, et al. Pharmacokinetics and safety of tipranavir/ritonavir alone or in combination with saquinavir, amprenavir or lopinavir: interim analysis of BI1182.51 [abstract 5.1]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; April 2004; Rome.
4. Abel S, Russell D, Taylor-Worth RJ, et al. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008; 65 (Suppl 1):27-37.
5. Hanley WD, Wenning LA, Moreau A, et al. Effect of tipranavir + ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53: 2752-2755.
6. González de Requena D, Calcagno A, Bonora S, et al. Unexpected drug- drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS 2006; 20:1977-1979.
7. Raffi F, Battegay M, Rusconi S, et al. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 2007; 21:1977-1980.
8. Curran A, Lopez R, Pou L, et al. Pharmacokinetic evaluation of potential interaction between tipranavir and enfuvirtide [abstract 53]. 7th International Workshop on Clinical Pharmacology of HIV Therapy; April 2006; Lisbon.
9. Hicks CB, Cahn P, Cooper DA, et al., RESIST investigator group. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimenof antiretroviral drugsfor treatment-experiencedHIV-1-infectedpatients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug resistant patients with Tipranavir (RESIST)studies: ananalysis ofcombineddata from two randomised open-label trials. Lancet 2006; 368:466-475.
10. Sulkowski M, Rockstroh J, Soriano V, Stern JO. Clinical course of increased LFTs and hepatic events associated with ritonavir (RTV)-boosted tipranavir (TPV/r) based therapy in RESIST Trials [abstract H-1899]. In: Program and abstracts of the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2006; San Francisco, CA.
11. Boehringer Ingelheim. Aptivus1 (tipranavir) capsules, 250 mg. US prescribing information [online]. http://bidocs.boehringer-ingelheim.com/ BIWebAccess/ ViewServlet.ser?docBase=renetnt&folderPath=/ Prescribing+Information/ PIs/Aptivus/10003515+US+01.pdf [Accessed 9 June 2009]
12. Justice AC, Zingmond DS, Gordon KS, et al., Veterans Aging Cohort Study Project Team. Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage? Clin Infect Dis 2008; 47:1226-1230.
13. Cahn P, Hicks C, for the RESIST-2 and RESIST-1 Study Teams, et al. RESIST-1 (R-1) and RESIST-2 (R-2) 48 week meta-analyses demonstrate superiority of protease inhibitor (PI) tipranavir + ritonavir (TPV/r) over an optimized comparator PI (CPI/r) regimen in antiretroviral (ARV) experienced patients. Tenth European AIDS Conference/European AIDS Clinical Society; Dublin; abstract PS3/8, 2005.
14. Baxter JD, Schapiro JM, Boucher CAB, et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006; 80:10794-10801.
15. Marcelin AG, Masquelier B, Descamps D, et al. Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2008; 52:3237-3243.
16. Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol 2007; 81:13845-13851.
17. Shen L, Peterson S, Sedaghat AR, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008; 14:762-766.
18. Sekar VJ, Lefebvre E, Boogaerts G, et al. Pharmacokinetic interaction between the PI TMC114 and lopinavir/ritonavir [abstract no. A-367]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27- 30 September 2006; San Francisco, CA.
19. Abel S, RidgwayC, Hamlin J, et al. An open, randomized, 2-way crossover study to investigate the effect of darunavir/ritonavir on the pharmacokinetics of maraviroc in healthy subjects [abstract no. 55 plus poster]. 8th InternationalWorkshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest.
20. Anderson MS, Sekar V, Tomaka F, et al. Pharmacokinetic evaluation of darunavir/ritonavir and raltegravir in healthy subjects [abstract A-962]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 2008; Washington.
21. Scholler-Gyure M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12:789-796. (Pubitemid 47235493)
22. Sekar V, De Paepe E, Vangeneugden T, et al. Absence of an interaction between the potent HIV protease inhibitor TMC114 and the fusion inhibitor enfuvirtide in the POWER 3 analysis [abstract no. P54 plus poster]. 7th International Workshop on Clinical Pharmacology of HIV Therapy; 20-22 April 2006; Lisbon.
23. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir- ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatmentexperienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370:49-58.
24. Tibotec Therapeutics. Prezista (darunavir) tablets full prescribing information (US) [online]. http://www.prezista.com/docs/us. [Accessed 3 June 2009]
25. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178.
26. De Meyer S, Dierynck I, Lathouwers E, et al. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatmentexperienced patients in POWER 1, 2, 3 and DUET-1 and 2. Antivir Ther 2008; 13 (Suppl 3):A33 (abstract 31).
27. Descamps D, Lambert-Niclot S, Marcelin AG, et al. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother 2009; 63:585-592.
28. Das K, Clark AD Jr, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. JMed Chem 2004; 47:2550-2560.
29. Scholler-Gyure M, Woodfall B, De Marez T, et al. Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir [abstract 278]. 8th International Congress on Drug Therapy in HIV Infection; November 2006; Glasgow.
30. Scholler-Gyure M, Woodfall B, Bollen S, et al. Pharmacokinetics of amprenavir and TMC125 in HIV-infected volunteers receiving TMC125 with fosamprenavir/ ritonavir [abstract A-370]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2006; San Francisco.
31. Anderson MS, Kakuda TN, Miller JL, et al. Pharmacokinetic evaluation of nonnucleoside reverse transcriptase inhibitor TMC125 and integrase inhibitor raltegravir in healthy subjects [abstract TUPDB02. 4th IAS Conference on HIV Pathogenesis, Treatment & Prevention; July 2007; Sydney.
32. Davis J, Scholler-Gyure M, Kakuda TN, et al. An open randomised two period crossover study in 2 cohorts to investigate the effect of steady state TMC125 and the combination of TMC125/DRV/r on the steady state pharmacokinetics of oral maraviroc in healthy subjects [abstract P4.3/02]. 11th European AIDS Conference; October 2007; Madrid.
33. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24- week results from a randomized, double-blind, placebo controlled trial. Lancet 2007; 370:29-38.
34. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced patients in DUET-2: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
35. Ruxrungtham K, Pedro RJ, Latiff GH, et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naÿve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med 2008; 9:883-896.
36. Nadler JP, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS 2007; 21:F1-F10.
37. Cheret A, Katlama C, Trottier B, et al. Pooled 48-Week Analysis of DUET-1 and DUET-2: durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients. 15th ISHEID 2008. Abstract PS 1/5.
38. Vingerhoets J, Peeters M, Azijn H, et al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. 17th International HIV Drug Resistance Workshop; 2008; poster 24.
39. Picchio G, Vingerhoets J, Staes M, et al. Prevalence of TMC125 resistanceassociated mutations in a large panel of clinical isolates [abstract 866]. Program and abstracts of rhe 15th Conference on Retroviruses and Opportunuistic Infections; 2008; Boston.
40. Llibre J, Santos J, Puig T, et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother 2008; 62:909-913.
41. TMC114-TiDP31-C229: This is a Study on the Effectiveness, Safety and Tolerability of Darunavir (DRV), Administered With Low-Dose Ritonavir (Rtv) as 800/100 mg Daily Versus 600/100mg Twice Per Day for HIV-1 Patients Over a 48-Week Treatment Period. (NCT00524368). http://clinicaltrials.gov/ ct2/show/NCT00524368?term=darunavir&rank=21